NCT06312189View on ClinicalTrials.gov

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Chorea, Huntington
Interventions
DRUG

Valbenazine

vesicular monoamine transporter 2 (VMAT2) inhibitor

Trial Locations (3)

V6T 2B5

Neurocrine Clinical Site, Vancouver

K1Y 4E9

Neurocrine Clinical Site, Ottawa

MK2 1E1

Neurocrine Clinical Site, Toronto

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY